Efficacy and Safety of KHN702 Tablets in Moderate to Severe Post-operative Pain Subjects

Efficacy and Safety of KHN702 Tablets in Moderate to Severe Post-operative Pain Patients: A Randomized, Double-blind, Placebo-Controlled, Phase Ib Trial

This study is a randomized, double-blind, placebo-controlled, parallel-group clinical trial. To preliminarily evaluate the safety and efficacy of KHN702 tablets in moderate to severe post-operative pain patients.

Study Overview

• Status: Not yet recruiting
• Conditions: Postoperative Pain
• Intervention / Treatment: Drug: KHN702; Drug: KHN702 placebo

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Mengchang Yang, Medical Doctor; Phone Number: 86-28-87393401; Email: ymc681@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subjects between the ages of 18 and 75 years, inclusive.
2. Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive.
3. Patients scheduled for surgery.
4. According to the researcher's medical judgment, American Society of Anesthesiologists (ASA) classification≤Grade II.
5. The subject can understand and comply with the study procedures and requirements, and can provide written informed consent prior to any study procedures.
6. NRS ≥ 4 points within 6 hours after surgery.

Exclusion Criteria:

1. Participants experiencing acute or chronic pain unrelated to the surgical site, which the investigator deems may confound the participant's assessment of postoperative pain.

2. History or evidence of any of the following conditions prior to screening:

   • History of significant cardiovascular or cerebrovascular disease;
   • Severe respiratory disease history;
   • Severe Neurological and Psychiatric disease History;
   • Active peptic ulcer disease, significant vomiting, chronic diarrhea, ileus, malabsorption, or other known conditions that significantly affect drug absorption, distribution, metabolism, or excretion;
   • Subjects at high risk of bleeding who are deemed unsuitable for this trial by the investigator;
3. Long-term use of opioids or nonsteroidal anti-inflammatory drugs within the past 30 days prior to screening, or discontinuation of medications affecting analgesic efficacy assessment (except those permitted by the protocol) less than 5 half-life prior to randomization.
4. Subjects with a history of opioid allergy, or those with a history of allergy to the intraoperative medications specified in the protocol, postoperative rescue analgesics, or known allergies to the investigational drug or its excipients.
5. Subjects who underwent major surgery within 3 months prior to screening and the investigator determined that it would affect postoperative pain assessment.
6. Any of the following infectious diseases were present during screening: Hepatitis B surface antigen (HBsAg) positive, hepatitis C virus antibody (HCV Ab) positive, human immunodeficiency virus antibody (HIV Ab) positive, or serum treponema pallidum antibody (TPAb) positive.
7. History of substance abuse or alcohol abuse within the three months prior to screening .
8. History of blood donation within the past three months prior to screening.
9. Individuals who have participated in any clinical research within the past three months prior to screening .
10. Pregnant or lactating women; women or men of reproductive potential who are unwilling to use contraception throughout the study period; or subjects (including male subjects) planning to conceive within 3 months after study completion.
11. Subjects with intraoperative blood loss exceeding 1000 mL or those experiencing other severe complications during surgery;
12. Subjects requiring intensive care following surgery;
13. Other circumstances deemed unsuitable for participation in this trial by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KHN702; Participants will be randomized to either the KHN702 tablet or placebo group, and administer study drug for 2 days.	Drug: KHN702; KHN702 tablet for oral administration
Placebo Comparator: KHN702 placebo; Participants will be randomized to either the KHN702 tablet or placebo group, and administer study drug for 2 days.	Drug: KHN702 placebo; KHN702 placebo tablet for oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Time-weighted the Sum of Pain Intensity Differences in Pain Score 0 to 48 hours after the first dose	48 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Maximum Plasma Concentration	48 hours
Safety：Incidence and severity of Adverse Events( AE)/SAE		from ICF signing date to day 7 since the first dose
Time-weighted the Sum of Pain Intensity Differences in Pain Score over Times		48 hours
Times and Cumulative Amount of Rescue Analgesics Used by Subjects within 0 to 48 Hours after the First Dose.		48 hours
Tmax	Time to Maximum Plasma Concentration	48 hours
AUC0-t	Area Under the concentration-time curve from zero to t	48 hours

Collaborators and Investigators

• Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): February 1, 2026
• Study Completion (Estimated): February 1, 2026

Study Registration Dates

• First Submitted: November 28, 2025
• First Submitted That Met QC Criteria: December 9, 2025
• First Posted (Actual): December 11, 2025

Study Record Updates

• Last Update Posted (Actual): December 11, 2025
• Last Update Submitted That Met QC Criteria: December 9, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Pain, Postoperative
• Other Study ID Numbers: KHN702-30102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No